

Involvement of α 1-adrenergic receptors in tranylcypromine enhancement of nicotine self-administration in rat

Anne-Sophie Villégier · Shahrddad Lotfipour ·
James D. Belluzzi · Frances M. Leslie

Received: 15 August 2006 / Accepted: 7 April 2007 / Published online: 8 May 2007
© Springer-Verlag 2007

Abstract

Rationale The mechanisms mediating tobacco addiction remain elusive. Nicotine, the psychoactive component in tobacco, is generally believed to be the main cause of reward and addiction. However, tobacco smoke contains thousands of constituents, some of which may interact with nicotine to enhance reward. It has previously been shown that monoamine oxidase (MAO) inhibition, known to result from smoking, can enhance nicotine self-administration. The aim of the present study was to evaluate the role of noradrenergic systems in mediating this enhancement of nicotine reward.

Objective The objective of this study was to test the hypothesis that MAO inhibitor pretreatment enhances nicotine self-administration by activation of noradrenergic pathways that regulate dopamine release in the nucleus accumbens (NAc).

Methods The effect of prazosin (0.0625–0.5 mg/kg, i.p.), a specific α 1-adrenergic receptor antagonist, was examined on male rats pretreated with tranylcypromine (3 mg/kg), an irreversible inhibitor of MAO A and B. Acquisition of nicotine (10 μ g kg⁻¹ inj⁻¹, i.v.) self-administration behavior was examined over a 5-day period. Nicotine (60 μ g kg⁻¹

inj⁻¹, i.v.)-induced increase in NAc extracellular dopamine levels was examined by in vivo microdialysis in non-self-administering animals.

Results We have shown that (1) tranylcypromine enhances nicotine self-administration, (2) prazosin pretreatment blocks both the acquisition and the expression of nicotine self-administration, and (3) prazosin pretreatment diminishes nicotine-induced dopamine release in the NAc.

Conclusion These data indicate that the stimulation of α 1-adrenergic receptors is critical for tranylcypromine enhancement of nicotine reward and suggest a critical interplay between the noradrenergic and dopaminergic systems in tobacco addiction.

Keywords Rat · MAOI · Tobacco · Prazosin · Norepinephrine · Nicotine · Tranylcypromine · Self-administration · Reward · Dopamine

Introduction

Tobacco is one of the most abused reinforcing agents in humans (Henningfield et al. 1998). Nicotine, the main psychoactive component in cigarettes, is generally believed to be the cause of tobacco addiction (Dani and Heinemann 1996; Balfour et al. 2000; Di Chiara 2000). However, when nicotine is tested in animal models of reward and addiction, it seems to be a weak reinforcer (Stolerman and Jarvis 1995). This paradox has led to the hypothesis that nicotine may interact with other constituents in tobacco smoke to produce its addictive effects (e.g., Belluzzi et al. 2005). There are more than 4,000 compounds in tobacco smoke (CDC 1989), some of which are known to irreversibly inhibit monoamine oxidase (MAO; Lewis et al. 2007). It is well established that both central and peripheral MAO

A.-S. Villégier (✉) · J. D. Belluzzi · F. M. Leslie
Department of Pharmacology, School of Medicine,
University of California,
Room 360, MS2,
Irvine, CA 92697, USA
e-mail: avillegi@uci.edu

S. Lotfipour · F. M. Leslie
Department of Anatomy and Neurobiology, School of Medicine,
University of California,
Irvine, CA 92697, USA

activities are irreversibly inhibited in smokers (Fowler et al. 1996b, 2003). Recent studies suggest that the inhibition of MAO activity by tobacco smoke may enhance the reinforcing effects of nicotine (Guillem et al. 2005; Villégier et al. 2003, 2005, 2006). Indeed, pretreatment with tranylcypromine, an irreversible and nonselective MAO inhibitor (MAOI), increases the rewarding properties of nicotine (Guillem et al. 2005; Villégier et al. 2005, 2006). Therefore, animal models of tobacco addiction may be improved by combining MAOI with nicotine to assess underlying mechanisms. Moreover, the use of MAOI has provided promising clinical data to help smokers quit smoking (Berlin et al. 1995; George et al. 2003; Biberman et al. 2003).

Until now, mechanistic studies of tobacco addiction have examined nicotine alone. Such studies suggest that nicotine exerts its reinforcing properties through the activation of mesolimbic dopaminergic transmission (Di Chiara et al. 1999). Nicotine stimulates the nicotinic acetylcholine receptors (nAChR) located on the mesolimbic system (Champtiaux et al. 2003) and increases the firing activity of the mesolimbic dopaminergic neurons, thus increasing extracellular concentration of dopamine (DA) in the nucleus accumbens (NAc; Nisell et al. 1996). However, because of the large representation of nAChRs through the brain, other systems may be of importance for nicotine-induced reward. Interestingly, nAChRs are localized on noradrenergic cell bodies and terminals (Lena et al. 1999), and nAChR-evoked release of norepinephrine (NE) has been demonstrated in several brain regions that receive noradrenergic innervation from the locus coeruleus (LC; Mitchell et al. 1989; Engberg and Hajos 1994; Leslie et al. 2002; O'Leary and Leslie 2003). Although a few reports have analyzed the involvement of NE in the rewarding properties of nicotine, its release by nicotine seems to deserve more attention. In fact, a physiological coupling between noradrenergic and dopaminergic neurons has been shown to occur through the stimulation of α 1-adrenergic receptors (Antelman and Caggiula 1977; Kokkinidis and Anisman 1978; Lategan et al. 1990). Moreover, noradrenergic transmission has been shown to exert a permissive effect on both biochemical and behavioral effects related to addictive processes. Amphetamine-induced locomotor hyperactivity and DA release are both inhibited by prazosin, an α 1-adrenergic antagonist, or by the genetic elimination of the α 1 receptor (Blanc et al. 1994; Darracq et al. 1998; Drouin et al. 2002a, b; Auclair et al. 2004).

In the present study, we have evaluated the possible involvement of noradrenergic transmission in nicotine-induced reward. To do so, we have tested the effect of prazosin on the acquisition and maintenance of nicotine self-administration in tranylcypromine pretreated-rats and

on nicotine-induced DA release in the NAc in non-self-administering animals.

Materials and methods

Animals

Male Sprague–Dawley rats were obtained at postnatal day (P)16 and P80. Juvenile animals remained with their dam until weaning (P21) when they were housed in groups of four until surgery. After surgery, all animals were single-housed and maintained on a 12-h light/dark cycle (lights on at 07:00 A.M.) with food and water available ad libitum. Rats were allowed at least 3 days of postoperative recovery before any treatments began. All tests were performed during the light part of the light–dark cycle to reproduce conditions used in studies showing the enhancement of nicotine self-administration by tranylcypromine (Villégier et al. 2007).

Drugs

Nicotine [(–) nicotine hydrogen tartrate], tranylcypromine hydrochloride, and prazosin were purchased from Sigma-Aldrich. Doses are expressed as salts for all compounds except for nicotine, which is expressed as free base. Tranylcypromine and nicotine were dissolved in saline (NaCl, 0.9%) and the pH adjusted to 7.4 with NaOH. Prazosin was dissolved in water. Tranylcypromine, prazosin, and vehicles were injected intraperitoneally (i.p.; 0.5 ml per injection), while nicotine and vehicles were injected intravenously (i.v.; 20 μ l per injection). DA stock solution was ordered as pre-made solutions from ESA with a concentration of 1 mg/ml. DA standard was stored at 2–8°C.

Self-administration

Surgical implantation of intravenous catheters Surgery commenced at ages P23–24 or P86–87, respectively. Animals were anesthetized with Equithesin (0.3 ml/100 g, i.p. for P86, 0.25 ml/100 g, i.p. for P23), and a chronic catheter was surgically implanted into the right external jugular vein (Belluzzi et al. 2005; Caine et al. 1993). Catheters were flushed daily with 0.2 ml sterile heparinized saline solution (0.6 or 0.3 ml of 1,000 U/ml heparin in 30 ml saline for P86 or P23, respectively) to maintain catheter patency. On test days, heparinized saline was injected before and after the self-administration session. Before testing and after the final daily test session, Propofol (0.2 ml P86; 0.1 ml P23) was injected through the catheter to test the patency of the i.v. catheter as indicated by rapid

(5–10 s) anesthesia. Data were discarded from all animals not demonstrating rapid anesthesia.

Drug self-administration The drug self-administration procedure was modified from that used previously (Belluzzi et al. 2005). Three to 4 days after surgery, rats were tested in self-administration chambers with two nose-poke holes side-by-side in the side of the chamber. A syringe, mounted in an infusion pump outside the test chamber, was filled with enough solution to provide a maximum of 200 injections. During each 1.1-s 20- μ l infusion, the signal light over the hole associated with drug injection went on for a 1.1-s period after which the house light went off and all responses were counted but had no effect for a 60-s period. Nose pokes at the reinforced and non-reinforced holes were followed by a 1-min timeout during which responses were not counted. The delivery of all experimental parameters and the collection of all data were controlled by a multi-channel computer system (MED Associates, St. Albans, VT, USA).

Acquisition of nicotine self-administration after pretreatment with tranlycypromine Initial acquisition of drug self-administration was measured during two postnatal periods that have previously been defined as early adolescence and adulthood (Spear 2000): P27–31 and P90–94. A nose-poke response was used, which relies on the animals' natural olfactory exploration to provide adequate initial levels of responding. Priming at the start of each session was not employed because of possible aversive effects of non-contingent injections in naive animals. A total of 163 rats were used in the experiment. Tests for acquisition of self-administration commenced without prior response training and consisted of five consecutive daily 3-h sessions with a fixed-ratio one (FR 1) reinforcement schedule. As we previously reported, tranlycypromine pretreatment shifts the dose–effect curve for nicotine self-administration to the left (Villégier et al. 2005, 2007). Animals show strong self-administration at nicotine doses as low as 2.5–10 μ g kg⁻¹ inj⁻¹ and no significant self-administration at the standard dose of 30 μ g kg⁻¹ inj⁻¹. For this reason, we chose to test the effect of prazosin on self-administration of nicotine 10 μ g kg⁻¹ inj⁻¹ in tranlycypromine pretreated rats. One hour before each session, rats received a pretreatment of tranlycypromine (3 mg/kg, i.p.) or vehicle (1.5 and 3 ml/kg, i.p. for adults and adolescents, respectively). Each nose-poke at the reinforced hole delivered nicotine (10 μ g/kg in 20 μ l) or saline vehicle (20 μ l). To control for nonspecific activating effects of drugs, non-reinforced nose-pokes (NR) at a second adjacent hole were counted but had no programmed consequences.

The involvement of the α 1-adrenergic receptor was tested by injecting a specific antagonist, prazosin (0.0625–

0.5 mg/kg, i.p.) or vehicle (1.5 and 3 ml/kg, i.p. for adults and adolescents, respectively), 30 min before the beginning of the self-administration session.

Microdialysis

Stereotaxic surgery Immediately after implantation of their intravenous catheter, animals for microdialysis were implanted with a cranial guide cannula (20 gauge; CMA/Microdialysis AB, Stockholm, Sweden) 2.0 mm above the target area, which was fixed to the skull with acrylic dental cement and sealed with a dummy cannula. Anatomical coordinates for NAc shell were established from the atlas of Paxinos and Watson (1986): antero-posterior, +2.0 mm relative to bregma; medio-lateral, \pm 1.2 mm; and dorso-ventral, 5.8 mm from dura.

Microdialysis procedure Animals were given 2 days to recover with daily handling after surgeries. Catheters were flushed daily, and animals were habituated to the microdialysis chambers for 5 min per day. Intravenous catheter patency was tested by propofol 1 day before the experiment. In vivo microdialysis studies were performed after 2 days of tranlycypromine pretreatment to mimic nicotine self-administration studies that illustrated an increase in reinforcing hole responding in tranlycypromine pretreated animals.

On the experimental day, the dummy cannula was replaced with a 2-mm microdialysis probe (CMA/12). The quality of probes was tested in vitro before the experiment with an average recovery of $10.8 \pm 1.7\%$, $n=16$. Microdialysis was carried out under a free-moving condition, with the probe continuously perfused with artificial cerebrospinal fluid (CSF; CMA Microdialysis N, Chelmsford, MA, USA) at a constant flow rate of 1.1 μ l/min delivered by a microinfusion pump (CMA/100 microdialysis). After a 3-h equilibration period, samples were collected every 20 min during 1 h. At the 60-min time point, a third tranlycypromine (3 mg/kg, i.p.) injection was given. Samples were collected for another 90 min, until DA levels returned to baseline. Prazosin (0.5 mg/kg, i.p.) was injected 30 min before the nicotine injections (two 30 μ g kg⁻¹ inj⁻¹ i.v., 1 min apart). Nicotine was not self-administered but injected by the experimenter. Samples were collected for a final 80 min. The drug treatment and data collection times were chosen to parallel behavioral experiments such that DA collection occurred in the time period analogous to peak self-administration. DA levels were quantified by high performance liquid chromatography with electrochemical detection (HPLC-ED). At the end of the experiment, rats were killed. Brains were put into a formaldehyde solution and cut on a microtome in serial coronal slices according to the atlas of Paxinos and Watson (1986). Histological

examination of microdialysis probes placement was subsequently made on coronal sections (Fig. 4).

HPLC-ED detection Microdialysate samples (20 μ l) were automatically injected by an ESA 542 refrigerated autosampler onto a 150 \times 3.2 mm ODS C¹⁸ column (ESA, Chelmsford MA, USA) connected to an ESA 580 HPLC pump. The column was kept at 35°C and perfused by MD-TM mobile phase (ESA) at a rate of 0.6 ml/min. DA levels were determined by an electrochemical ESA 5600 detector connected to a 5014B Microdialysis Cell (ESA) with the dominant potential set to 320 mV. The sensitivity of the detector is 500 fg. Measurements were analyzed using CoulArray for Windows³² Software 2.0 (ESA). Standard curves were generated with DA (ESA) and DOPAC (Sigma-Aldrich, St. Louis, MO, USA) standards, and levels in experimental samples were determined from the curve and expressed as pg/20 μ l, unadjusted for recovery. For the effects of tranlycypromine, baseline levels of DA were determined by averaging the three samples before tranlycypromine injection (T20–T60). For nicotine's effects, the period before the nicotine injection (T180) was used as the baseline.

Statistics

Data were analyzed using two-way analysis of variance (ANOVA; for reinforced/nonreinforced responding \times day with repeated measures on reinforced/nonreinforced responding and on days and for treatment dose \times time with

repeated measures on time) and one-way ANOVA (for treatment and reinforced/nonreinforced effects). Significant main effects or interactions were tested separately with ANOVAs and Bonferroni- or Dunnett's-corrected post hoc comparisons. Day and reinforced/nonreinforced responding were considered as within-subject factors and pharmacological treatments corresponded to independent groups of animals and were considered as between-subject factors. All data analyses were performed using SYSTAT 10 statistical software. Statistical significance was set at $p < 0.05$.

Results

Prazosin blockade of acquisition of nicotine self-administration

As has been reported previously, in our acquisition paradigm in which there is no prior training or food deprivation, nicotine alone is not reliably self-administered (Belluzzi et al. 2005; Villégier et al. 2005, 2006). However, as shown in Fig. 1a, rats pretreated with tranlycypromine (3 mg/kg, i.p.) quickly learned to self-administer nicotine and displayed sustained self-administration at rates substantially higher than those for saline (significant nicotine dose effect, $F_{1,24}=5.275$, $p=0.031$ tranyl + nico R vs tranyl + saline R; and significant nicotine dose \times day interaction, $F_{4,96}=5.013$, $p=0.035$). Moreover, nicotine-reinforced responding was significantly higher than nonreinforced responding (Fig. 1a, $F_{1,13}=15.515$, $p=0.002$) with a significant rein-




Fig. 1 Prazosin blocks tranlycypromine-enhanced acquisition of nicotine self-administration. Before the beginning of each self-administration session, rats received an injection of tranlycypromine (3 mg/kg, i.p.) 1 h prior and an injection of either prazosin (0.5 mg/kg, i.p.) or vehicle (2 ml/kg, i.p.) 30 min prior. Rats were offered either nicotine (10 μ g kg⁻¹ inj⁻¹ in 20 μ l, i.v.; filled squares for reinforced responding and open squares for nonreinforced responding) or saline (20 μ l, i.v.; filled triangles for reinforced responding and open triangles for nonreinforced responding). The mean (\pm SEM) total responses are plotted daily for each treatment group. **a** Acquisition of

nicotine self-administration in tranlycypromine-pretreated rats. Rats pretreated with tranlycypromine self-injected significantly more nicotine than saline; * $p < 0.05$, ** $p < 0.01$. Moreover, reinforced responding for nicotine was significantly greater than responding at the non-reinforced hole, # $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$; $n=12-14$ /group. **b** Effect of prazosin on the acquisition of nicotine self-administration. In tranlycypromine/prazosin-treated rats, nicotine and saline reinforced responding were not significantly different ($p > 0.05$), and nicotine reinforced responding was not significantly different from responding at the nonreinforced hole ($p > 0.05$); $n=6-17$ /group




Fig. 2 Prolonged blockade of tranylcypromine-enhanced nicotine self-administration acquisition by prazosin. Prazosin (0.5 mg/kg, i.p.) or vehicle (3 ml/kg, i.p.) was administered 30 min prior to testing on days 1–3 (arrows). On days 4 and 5, all rats received a vehicle pretreatment. The mean (\pm SEM) total responses obtained on reinforced and nonreinforced holes are plotted for daily 3-h periods. * p <0.05, ** p <0.01, *** p <0.001 vs vehicle nonreinforced (NR); # p <0.05 vs prazosin reinforced (R); n =8–9/group

forced/nonreinforced \times day interaction ($F_{4,52}=4.902$, $p=0.002$). As shown in Fig. 1b, nicotine self-administration did not occur when prazosin (0.5 mg/kg, i.p.) was injected before each test session, as shown by the absence of difference between responding for nicotine and saline. Moreover, we did not obtain any significant difference between reinforced and nonreinforced responding and any reinforced/nonreinforced \times time interaction.

Prazosin significantly increased nonreinforced responding (significant prazosin effect in nicotine i.v. group: $F_{1,26}=10.288$, $p=0.004$; and in saline i.v. group: $F_{1,16}=6.659$, $p=0.02$ and significant time \times prazosin interaction in saline i.v. group: $F_{4,64}=3.517$, $p=0.012$).

Prazosin administration before early test sessions produced a prolonged blockade of nicotine self-administration. Figure 2 shows the time course of acquisition of nicotine self-administration in rats receiving either vehicle or prazosin on days 1–3, with all animals receiving vehicle on days 4 and 5. When nicotine self-administration was analyzed on days 4 and 5, a significant difference was found in reinforced vs nonreinforced responding ($F_{1,15}=8.153$, $p=0.012$) with a prazosin \times reinforced/nonreinforced responding interaction ($F_{1,15}=9.498$, $p=0.008$). Reinforced responding was significantly higher than responding at the nonreinforced hole on days 4 and 5 in rats pretreated with saline on days 1 to 3 ($F_{1,7}=64.571$, $p<0.001$) but not in rats receiving a prazosin pretreatment. Moreover, rats receiving prazosin treatment on days 1–3 had significantly lower responding at the reinforced hole on day 5 than vehicle-treated rats ($F_{1,15}=7.822$, $p=0.014$).

Prazosin blockade of established nicotine self-administration

Figure 3a shows the effect of prazosin on tranylcypromine-pretreated rats once nicotine self-administration has been established. Analysis across the first three daily sessions showed a significant difference between nicotine reinforced and nonreinforced responding ($F_{1,6}=88.803$, $p<0.001$). However, the administration of prazosin (0.5 mg/kg, i.p.) 30 min before self-administration testing on days 4 and 5 abolished the difference between reinforced and nonreinforced responding. Moreover, prazosin significantly reduced nicotine intake on days 4 and 5 when compared with day 3 ($p<0.001$ and $p=0.023$, respectively). Figure 3b shows that this inhibitory effect of prazosin was dose





Fig. 3 Acute reduction of tranylcypromine-enhanced nicotine intake by prazosin. **a** Rats were pretreated with tranylcypromine (3 mg/kg, i.p.) 1 h prior to nicotine self-administration sessions. The mean (\pm SEM) total responses obtained on reinforced and nonreinforced holes are plotted daily. On days 4 and 5, rats received a pretreatment with prazosin (0.5 mg/kg, i.p.; arrows); * p <0.05, *** p <0.001 reinforced vs

nonreinforced responding; $n=7$ /group. **b** On day 4, rats received prazosin 0.065, 0.125, 0.25, or 0.5 mg/kg (i.p.) or vehicle (3 ml/kg, i. p.). The mean (\pm SEM) total responses obtained at the reinforced hole during the 3-h period of the test day are plotted for each treatment group. ** p <0.01, *** p <0.001 vs vehicle treated rats; $n=4$ –9/group

Fig. 4 Photomicrograph localization of microdialysis probes in the NAc shell as shown by a representative **a** cresyl violet stained brain section and **b** schematic brain section from the Paxinos and Watson atlas. The dashed lines in **b** illustrate the positioning of the 2-mm membrane of the microdialysis probe



dependent. Analysis of the effect of prazosin on responding for nicotine self-administration after tranylcypromine showed a significant effect of dose ($F_{4,25}=8.916$, $p<0.001$). Nicotine self-administration was significantly decreased after prazosin treatment at doses of 0.125 mg/kg.

Effect of prazosin on tranylcypromine enhancement of nicotine-induced DA release

Tranylcypromine (3 mg/kg, i.p.) produced a significant ($F_{5,70}=13.366$, $p<0.0001$) increase in extracellular DA levels, but there were no statistical differences between prazosin or nicotine treatment groups, and the data were collapsed across treatments (Fig. 5a). After injections at

180 min (Fig. 5b), there were significant effects of nicotine ($F_{1,14}=31.778$, $p=0.0001$) and prazosin ($F_{1,14}=8.230$, $p=0.0124$). Nicotine (60 $\mu\text{g}/\text{kg}$, i.v.) significantly increased extracellular DA levels in the NAc shell of tranylcypromine pretreated rats for 40 min after administration, whereas prazosin significantly reduced the nicotine-induced DA levels (Fig. 5b).

Discussion

In the present study, we have shown the involvement of noradrenergic systems in mediating tranylcypromine enhancement of nicotine self-administration. Prazosin, a specific α_1 -adrenergic receptor antagonist, inhibits both




Fig. 5 Prazosin reduces tranylcypromine-enhanced nicotine stimulated increase of extracellular DA levels in NAc. **a** After a 60-min baseline period, tranylcypromine (3 mg/ml, i.p.) was injected and DA levels in NAc were recorded for 120 min. Tranylcypromine significantly increased DA levels over baseline for 80 min after injection. Extracellular DA levels are expressed as mean percentage baseline, where the baseline is the mean pg/20 μl for T20–T60 min. *** $p<0.001$ vs baseline; ** $p<0.01$; $n=18$. **b** Ninety minutes after the

injection of tranylcypromine (3 mg/kg, i.p.), rats received an injection of either prazosin (0.5 mg/kg, i.p.) or vehicle (3 ml/kg, i.p.). Nicotine (30 $\mu\text{g}/\text{kg}$, i.v. $\times 2$) or saline (20 μl , i.v. $\times 2$) was injected 30 min later. Extracellular DA levels are expressed as mean percentage baseline, where the baseline is the pg/20 μl for T180 min. Nicotine significantly increased extracellular DA levels in tranylcypromine pretreated rats but not after administration of prazosin. *** $p<0.001$ vs Veh–Nic; ** $p<0.01$; * $p<0.05$; ++ $p\leq 0.01$ vs T180; $n=3-7/\text{group}$

the acquisition and expression of nicotine self-administration in tranylcypromine pretreated rats. Furthermore, prazosin pretreatment reduced nicotine-induced DA release in the NAc. Taken together, these results suggest a critical interplay between noradrenergic and dopaminergic systems in tobacco reward.

Nicotine and MAOI as a model of smoking

We have replicated previous findings that MAOI pretreatment enhances nicotine self-administration in a rigorous acquisition paradigm in which untreated rats do not respond (Villégier et al. 2005, 2006). As there are natural MAOIs contained in tobacco, we have proposed that the combined use of nicotine and MAOIs may be a better model than the use of nicotine alone to assess the rewarding effects of tobacco. Although it is well established that smoking reduces MAO-A and MAO-B activities in smoker's brains and peripheral tissues (Fowler et al. 1996a, b), the irreversible MAOI in tobacco has not yet been identified (Lewis et al. 2007). We have therefore used tranylcypromine, an irreversible MAOI, which inhibits both MAO-A and MAO-B within 1 h of administration (Baker et al. 1992; Griebel et al. 1998). The tranylcypromine dose used in our study is consistent with previous investigations on the MAO-inhibiting effects of this drug (McManus and Greenshaw 1991a, b; Todd and Baker 1995). Moreover, we have confirmed that tranylcypromine-pretreatment inhibits MAO-A and MAO-B by 80 and 90%, respectively (data not shown).

NE in nicotine-induced reward

Although nicotine-induced release of NE has been demonstrated in several brain regions (Mitchell et al. 1989; Summers and Giacobini 1995; Fu et al. 1999a, b; Lena et al. 1999; Li and Eisenach 2002), it has rarely been correlated with nicotine-induced reward. In the present study, the blockade of $\alpha 1$ -adrenergic receptors reduced both nicotine self-administration of tranylcypromine-treated rats and extracellular DA levels in the NAc measured in non-self-administering, tranylcypromine-pretreated rats. This finding suggests that in animals pretreated with a MAOI, nicotine exerts its rewarding properties through an activation of NAc DA terminals that are under the permissive control of NE transmission. This observation is in accordance with previous reports describing the modulatory action of noradrenergic transmission on dopaminergic functions (Darracq et al. 1998; Linner et al. 2001; Auclair et al. 2002). Studies have provided evidence that the burst firing of the dopaminergic neurons are inhibited by an $\alpha 1$ -adrenergic receptor antagonist, prazosin (Grenhoff et al. 1993; Grenhoff and Svensson 1993; Andersson et al.

1994), and increased by a blocker of NE reuptake, reboxetine, or nisoxetine (Shi et al. 2000; Linner et al. 2001).

Although it has recently been suggested that prazosin at a dose of 0.5 mg/kg can block motivational processes in general, including food-seeking behavior, a lower dose of 0.3 ml/kg has been shown to selectively inhibit both cocaine-induced reinstatement of drug-seeking behavior (Zhang and Kosten 2005) and cocaine priming of subsequent self-administration (Zhang and Kosten 2006). Our present finding of significant effects of prazosin at doses as low as 0.125 mg/kg suggests a specific role of $\alpha 1$ -adrenergic receptors in tranylcypromine-enhanced nicotine reinforcement.

Noradrenergic stimulation may be mediated by $\alpha 1b$ -adrenergic receptors, as KO mice for these receptors show a deficit in locomotor hyperactivity, conditioned place preference, and oral preference induced by psychostimulants and opiates, and elimination of D-amphetamine-induced increases in extracellular DA levels in the NAc (Drouin et al. 2002a, b; Auclair et al. 2004). Ventral tegmental area (VTA)-dopaminergic cell bursting activities may be controlled by $\alpha 1$ -adrenergic transmission located in the prefrontal cortex (PFC), as intra-PFC prazosin administration reduces both D-amphetamine-induced DA release in the NAc and locomotor hyperactivity in rat (Blanc et al. 1994; Darracq et al. 1998). Anatomically, glutamatergic afferents originating from several areas, including the PFC (Gariano and Groves 1988; Sesack and Pickel 1992; Chergui et al. 1993; Darracq et al. 1998), could be at the origin of this control, as they are regulated by $\alpha 1$ -adrenergic receptors and provide an excitatory input to the mesolimbic dopaminergic cells on cell bodies and terminals (Trovero et al. 1994; Lu et al. 1997; Li et al. 1999; Carr and Sesack 2000; Darracq et al. 2001). Alpha1b-adrenergic receptors located in the VTA may also be important to control DA mesolimbic cells, which have been implicated in behavioral sensitization to psychostimulants (Vezina 1993).

Conclusion

This study provides support for the view that $\alpha 1$ -adrenergic transmission plays an important role in tobacco addiction and may, therefore, be a useful therapeutic target. According to some theories, vulnerability and individual sensitivity to drugs of abuse, such as psychostimulants and opiates, may be explained by genetic or epigenetic variations in the reactivity of noradrenergic neurons to environmental cues affecting the activation of VTA dopaminergic neurons (O'Brien et al. 1986; Piazza et al. 1989; Shiffman 1991; Hooks et al. 1991; Tassin 1998). The present study tends to generalize this theory to tobacco addiction. Alpha1-adrenergic transmission may then be a

common mechanism driving addiction regardless of the addictive substance class.

Acknowledgments This work was supported by PHS Grant DA21267 and a fellowship from TRDRP 13DT-0033 (S.L). Experiments comply with the current laws of the country in which they were performed. All experimental procedures were performed in compliance with NIH Guide for Care and Use of Laboratory Animals (NIH No 85-23, rev. 1985) and approved by the UCI Institutional Animal Care and Use Committee.

References

- Andersson JL, Marcus M, Nomikos GG, Svensson TH (1994) Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. *Naunyn Schmiedebergs Arch Pharmacol* 349:236–243
- Antelman SM, Caggiola AR (1977) Norepinephrine-dopamine interactions and behavior. *Science* 195:646–653
- Auclair A, Cotecchia S, Glowinski J, Tassin JP (2002) D-Amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release. *J Neurosci* 22:9150–9154
- Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin JP (2004) 5-HT_{2A} and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. *Eur J Neurosci* 20:3073–3084
- Baker GB, Coutts RT, McKenna KF, Sherry-McKenna RL (1992) Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. *J Psychiatry Neurosci* 17:206–214
- Balfour D, Benowitz N, Fagerstrom K, Kunze M, Keil U (2000) Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. *Eur Heart J* 21:438–445
- Belluzzi JD, Wang R, Leslie FM (2005) Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. *Neuropsychopharmacology* 30(4):705–712
- Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, Lecrubier Y, Puech AJ (1995) A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. *Clin Pharmacol Ther* 58(4):444–452
- Biberman R, Neumann R, Katzir I, Gerber Y (2003) A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. *Addiction* 98(10):1403–1407
- Blanc G, Trovero F, Vezina P, Herve D, Godeheu AM, Glowinski J, Tassin JP (1994) Blockade of prefronto-cortical alpha 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical D-amphetamine injection. *Eur J Neurosci* 6:293–298
- Caine SB, Lintz R, Koob GF (1993) Intravenous drug self-administration techniques in animals. In: Sahagal A (ed) *Behavioural neuroscience, vol. II: A practical approach*. Oxford University Press, Oxford, pp 117–143
- Carr DB, Sesack SR (2000) Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. *J Neurosci* 20:3864–3873
- CDC (1989) Reducing the health consequences of smoking: 25 years of progress—a report of the Surgeon General, chap. 2. US Department of Health and Human Services, CDC, DHHS publication, Rockville, MD, USA, pp 79–92
- Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Lena C, Clementi F, Moretti M, Rossi FM, Le Novère N et al (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. *J Neurosci* 23:7820–7829
- Chergui K, Charléty P, Akaoka H, Saunier C, Brunet J, Buda M, Svensson T, Chouvet G (1993) Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons. *In Vivo Eur J Neurosci* 5:137–144
- Dani JA, Heinemann S (1996) Molecular and cellular aspects of nicotine abuse. *Neuron* 16:905–908
- Darracq L, Blanc G, Glowinski J, Tassin JP (1998) Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. *J Neurosci* 18:2729–2739
- Darracq L, Drouin C, Blanc G, Glowinski J, Tassin JP (2001) Stimulation of metabotropic but not ionotropic glutamatergic receptors in the nucleus accumbens is required for the D-amphetamine-induced release of functional dopamine. *Neuroscience* 103:395–403
- Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. *Eur J Pharmacol* 393:295–314
- Di Chiara G, Tanda G, Bassareo V, Pontieri F, Acquas E, Fenu S, Cadoni C, Carboni E (1999) Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. *Ann N Y Acad Sci* 877:461–485
- Drouin C, Blanc G, Villégier AS, Glowinski J, Tassin JP (2002a) Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics. *Synapse* 43:51–61
- Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia S, Tassin JP (2002b) Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. *J Neurosci* 22:2873–2884
- Engberg G, Hajos M (1994) Nicotine-induced activation of locus coeruleus neurons—an analysis of peripheral versus central induction. *Naunyn Schmiedebergs Arch Pharmacol* 349:443–446
- Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, et al (1996a) Inhibition of monoamine oxidase B in the brains of smokers. *Nature* 379:733–736
- Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulakova I, Wolf AP (1996b) Brain monoamine oxidase A inhibition in cigarette smokers. *Proc Natl Acad Sci USA* 93:14065–14069
- Fowler JS, Logan J, Wang GJ, Volkow ND, Telang F, Zhu W, Franceschi D, Pappas N, Ferrieri R, Shea C et al (2003) Low monoamine oxidase B in peripheral organs in smokers. *Proc Natl Acad Sci USA* 100:11600–11605
- Fu Y, Matta SG, McIntosh JM, Sharp BM (1999a) Inhibition of nicotine-induced hippocampal norepinephrine release in rats by alpha-conotoxins MII and AuIB microinjected into the locus coeruleus. *Neurosci Lett* 266:113–116
- Fu Y, Matta SG, Sharp BM (1999b) Local alpha-bungarotoxin-sensitive nicotinic receptors modulate hippocampal norepinephrine release by systemic nicotine. *J Pharmacol Exp Ther* 289:133–139
- Gariano RF, Groves PM (1988) Burst firing induced in midbrain dopamine neurons by stimulation of the medial prefrontal and anterior cingulate cortices. *Brain Res* 462:194–198
- George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS (2003) A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. *Biol Psychiatry* 53(2):136–143
- Grenhoff J, Svensson TH (1993) Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. *Eur J Pharmacol* 233:79–84

- Grenhoff J, Nisell M, Ferre S, Aston-Jones G, Svensson TH (1993) Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. *J Neural Transm Gen Sect* 93:11–25
- Griebel G, Curet O, Perrault G, Sanger DJ (1998) Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. *Neuropharmacology* 37:927–935
- Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M, Stinus L (2005) Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. *J Neurosci* 25:8593–8600
- Henningfield JE, Benowitz NL, Slade J, Houston TP, Davis RM, Deitchman SD (1998) Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. *Tob Control* 7:281–293
- Hooks MS, Jones GH, Smith AD, Neill DB, Justice JB Jr (1991) Response to novelty predicts the locomotor and nucleus accumbens dopamine response to cocaine. *Synapse* 9:121–128
- Kokkinidis L, Anisman H (1978) Involvement of norepinephrine in startle arousal after acute and chronic d-amphetamine administration. *Psychopharmacology (Berl)* 59:285–292
- Lategan AJ, Marien MR, Colpaert FC (1990) Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. *Brain Res* 523:134–138
- Lena C, de Kerchove D'Exaerde A, Cordero-Erausquin M, Le Novere N, del Mar Arroyo-Jimenez M, Changeux JP (1999) Diversity and distribution of nicotinic acetylcholine receptors in the locus coeruleus neurons. *Proc Natl Acad Sci USA* 96:12126–12131
- Leslie FM, Gallardo KA, Park MK (2002) Nicotinic acetylcholine receptor-mediated release of [3H]norepinephrine from developing and adult rat hippocampus: direct and indirect mechanisms. *Neuropharmacology* 42:653–661
- Lewis A, Miller JH, Lea RA (2007) Monoamine oxidase and tobacco dependence. *Neurotoxicology* 28:182–195
- Li X, Eisenach JC (2002) Nicotinic acetylcholine receptor regulation of spinal norepinephrine release. *Anesthesiology* 96:1450–1456
- Li Y, Hu XT, Berney TG, Vartanian AJ, Stine CD, Wolf ME, White FJ (1999) Both glutamate receptor antagonists and prefrontal cortex lesions prevent induction of cocaine sensitization and associated neuroadaptations. *Synapse* 34:169–180
- Linner L, Endersz H, Ohman D, Bengtsson F, Schalling M, Svensson TH (2001) Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. *J Pharmacol Exp Ther* 297:540–546
- Lu W, Chen H, Xue CJ, Wolf ME (1997) Repeated amphetamine administration alters the expression of mRNA for AMPA receptor subunits in rat nucleus accumbens and prefrontal cortex. *Synapse* 26:269–280
- McManus DJ, Greenshaw AJ (1991a) Differential effects of antidepressants on GABAB and beta-adrenergic receptors in rat cerebral cortex. *Biochem Pharmacol* 42:1525–1528
- McManus DJ, Greenshaw AJ (1991b) Differential effects of chronic antidepressants in behavioural tests of beta-adrenergic and GABAB receptor function. *Psychopharmacology (Berl)* 103:204–208
- Mitchell SN, Brazell MP, Joseph MH, Alavijeh MS, Gray JA (1989) Regionally specific effects of acute and chronic nicotine on rates of catecholamine and 5-hydroxytryptamine synthesis in rat brain. *Eur J Pharmacol* 167:311–322
- Nisell M, Nomikos GG, Hertel P, Panagis G, Svensson TH (1996) Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. *Synapse* 22:369–381
- O'Brien C, Ehrman R, Terns J (1986) Classical conditioning in human. In: Goldberg S, Stlerman I (eds) *Behavioral analysis of drug dependence*. Academic, London, pp 329–338
- O'Leary KT, Leslie FM (2003) Developmental regulation of nicotinic acetylcholine receptor-mediated [3H]norepinephrine release from rat cerebellum. *J Neurochem* 84:952–959
- Paxinos G, Watson C (1986) *The rat brain in stereotaxic coordinates*. Academic, New York
- Piazza PV, Deminiere JM, Le Moal M, Simon H (1989) Factors that predict individual vulnerability to amphetamine self-administration. *Science* 245:1511–1513
- Sesack SR, Pickel VM (1992) Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. *J Comp Neurol* 320:145–160
- Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS (2000) Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. *J Neurosci* 20:3504–3511
- Shiffman S (1991) Refining models of dependence: variations across persons and situations. *Br J Addict* 86:611–615
- Spear LP (2000) The adolescent brain and age-related behavioral manifestations. *Neurosci Biobehav Rev* 24:417–463
- Stolerman IP, Jarvis MJ (1995) The scientific case that nicotine is addictive. *Psychopharmacology (Berl)* 117:2–10
- Summers KL, Giacobini E (1995) Effects of local and repeated systemic administration of (–)nicotine on extracellular levels of acetylcholine, norepinephrine, dopamine, and serotonin in rat cortex. *Neurochem Res* 20:753–759
- Tassin JP (1998) Norepinephrine-dopamine interactions in the prefrontal cortex and the ventral tegmental area: relevance to mental diseases. *Adv Pharmacol* 42:712–716
- Todd KG, Baker GB (1995) GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (–)deprenyl and clorgyline. *J Affect Disord* 35:125–129
- Trovero F, Marin P, Tassin JP, Premont J, Glowinski J (1994) Accelerated resensitization of the D1 dopamine receptor-mediated response in cultured cortical and striatal neurons from the rat: respective role of α 1 adrenergic and N-methyl aspartate receptor. *J Neurosci* 14:6208–6218
- Vezina P (1993) Amphetamine injected into the ventral tegmental area sensitizes the nucleus accumbens dopaminergic response to systemic amphetamine: an in vivo microdialysis study in the rat. *Brain Res* 605:332–337
- Villégier AS, Blanc G, Glowinski J, Tassin JP (2003) Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors. *Pharmacol Biochem Behav* 76:267–274
- Villégier AS, Loftipour S, Belluzzi J, Leslie FM (2005) Involvement of α 1-adrenergic receptors in tranylcypromine enhancement of nicotine self-administration. 2005 Abstract Viewer/Itinerary Planner, Session No. 1027. Program No. 1027.5, Society for Neuroscience, Washington, DC, USA (online)
- Villégier AS, Salomon L, Granon S, Changeux JP, Belluzzi JD, Leslie FM, Tassin JP (2006) Monoamine Oxidase Inhibitors Allow Locomotor and Rewarding Responses to Nicotine. *Neuropsychopharmacology* 31(8):1704–1713
- Villégier AS, Loftipour S, McQuown CS, Belluzzi J, Leslie FM (2007) Tranylcypromine enhancement of nicotine self-administration. *Neuropharmacology* 52(6):1415–1425
- Zhang XY, Kosten TA (2005) Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. *Biol Psychiatry* 57:1202–1204
- Zhang XY, Kosten TA (2006) Previous exposure to cocaine enhances cocaine self-administration in an alpha 1-adrenergic receptor dependent manner. *Neuropsychopharmacology* 32(3):638–645